Curevo is a clinical-stage biotech firm developing adjuvanted subunit vaccines to enhance immune responses against infectious diseases. Their approach aims to improve vaccine efficacy and safety, addressing the need for more effective immunization strategies in public health.
Funding
$96.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current vaccines may not always provide sufficient protection, especially against emerging infectious diseases or in populations with weakened immune systems. Traditional vaccine approaches may also have limitations in terms of safety, tolerability, or the breadth and durability of the immune response they elicit.
Solution
Curevo develops a new generation of adjuvanted subunit vaccines designed to enhance immune responses against infectious diseases. Their vaccine technology focuses on improving vaccine efficacy and safety profiles by utilizing specific antigens combined with novel adjuvants. This approach aims to stimulate a more robust and durable immune response compared to traditional vaccines, addressing the need for more effective immunization strategies, particularly for vulnerable populations and against evolving pathogens.
Target Audience
The primary target audience includes individuals at risk of infectious diseases, public health organizations seeking improved immunization strategies, and populations with weakened immune systems who may benefit from enhanced vaccine efficacy.
Features
- Adjuvanted subunit vaccine platform for targeted immune response enhancement
- Focus on improved safety and tolerability profiles compared to traditional vaccines
- Development of vaccines against emerging and existing infectious diseases